Form 4: PTC Therapeutics Executive Sells Shares to Cover Tax Obligations
SEC Form 4
Lee Scott Golden, EVP & Chief Medical Officer of PTC Therapeutics, sold 897 shares of common stock on April 2, 2025, to cover tax obligations related to vesting RSUs.
Summary
- Lee Scott Golden, an executive at PTC Therapeutics, sold 897 shares of the company's common stock on April 2, 2025.
- The sale was executed at a price of $46.95 per share.
- This transaction was conducted to cover tax withholding obligations associated with the vesting of 2,100 Restricted Stock Units (RSUs) from a grant made on April 24, 2023.
- Following the transaction, Golden directly owns 75,997 shares of PTC Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine transaction for tax purposes and doesn't necessarily reflect a positive or negative outlook on the company's performance.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This transaction is a common practice where executives sell shares to cover tax obligations arising from the vesting of stock awards.
Key Dates
| Date | Description |
|---|---|
| 04/24/2023 | Date of the grant of 8,400 RSUs, of which 2,100 vested. |
| 04/02/2025 | Date of the share sale transaction. |
| 04/04/2025 | Date of signature on the Form 4 filing. |
Keywords
PTC Therapeutics, Lee Scott Golden, Form 4, share sale, RSUs, tax obligations, executive compensation, insider trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.